Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

RIGEL PHARMACEUTICALS INC: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Armistice Capital, LLC amended its Schedule 13G stake filing for Rigel Pharmaceuticals Inc., disclosing the change to the SEC under accession number 0001172661-26-005251. The filing updates the investment firm's previously reported beneficial ownership position in the drugmaker. Schedule 13G amendments are typically filed by passive investors when their holdings cross or adjust around the 5% threshold, making the disclosure a signal of shifting institutional interest in Rigel. Investors will watch for the specific share count and percentage in the amended filing to gauge whether Armistice added to or trimmed its position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Armistice Capital, LLC, Rigel Pharmaceuticals Inc